Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a ‘melphalan recall’ reaction

Bone Marrow Transplantation volume 45, pages 21–24 (2010)Cite this article

Abstract

Aggressive treatment with high-dose i.v. melphalan followed by auto-SCT (HDM/SCT) is effective in inducing hematological and clinical remissions, and in extending survival in AL amyloidosis. Tandem cycles of HDM/SCT have been shown to increase hematologic complete response rates in patients with AL amyloidosis. Between April 1994 and July 2008, 57 patients with AL amyloidosis at the Boston University Medical Center were treated with a second cycle of HDM/SCT after failing to achieve a complete response after a first transplantation. A total of 11 of 57 patients (19%) treated with tandem transplantation developed high fever 12–24 h after melphalan administration. The average peak temperature was 39.1 °C. Other clinical features include hypotension, acute renal failure and skin rash. No infectious etiology was identified. One of the patients had serum available for measurement of cytokines before, during and after the febrile reaction. The concentration of several pro-inflammatory cytokines, including IL-6 and TNFα, increased significantly, showing a clear physiological response correlating with the clinical findings. We conclude that an unusual cytokine-mediated febrile reaction can occur in patients with AL amyloidosis exposed to a second cycle of high-dose melphalan, which we have termed a ‘melphalan recall’ reaction.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Falk RH, Comenzo RL, Skinner M . The systemic amyloidoses. N Engl J Med 1997; 337: 898–909.

    Article  CAS  PubMed  Google Scholar 

  2. Merlini G, Westermark P . The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med 2004; 255: 159–178.

    Article  CAS  PubMed  Google Scholar 

  3. Sanchorawala V . Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol 2006; 1: 1331–1341.

    Article  PubMed  Google Scholar 

  4. Seldin DC, Anderson JJ, Sanchorawala V, Malek K, Wright DG, Quillen K et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 2004; 104: 1888–1893.

    Article  CAS  PubMed  Google Scholar 

  5. Sanchorawala V, Wright DG, Quillen K, Finn KT, Dember LM, Berk JL et al. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplant 2007; 40: 557–562.

    Article  CAS  PubMed  Google Scholar 

  6. Knight PR, Sreekumar A, Siddiqui J, Laxman B, Copeland S, Chinnaiyan A et al. Development of a sensitive microarray immunoassay and comparison with standard enzyme-linked immunoassay for cytokine analysis. Shock 2004; 21: 26–30.

    Article  CAS  PubMed  Google Scholar 

  7. Dennis L, Kasper EB, Fauci AS, Hauser SL, Longo DL, Jameson JL et al. (eds). Harrison's Principles of Internal Medicine, 16th edn. TheMcGraw-Hill Companies Inc.: Columbus, OH, USA, 2005.

    Google Scholar 

  8. Negussie Y, Remick DG, DeForge LE, Kunkel SL, Eynon A, Griffin GE . Detection of plasma tumor necrosis factor, interleukins 6, and 8 during the Jarisch-Herxheimer Reaction of relapsing fever. J Exp Med 1992; 175: 1207–1212.

    Article  CAS  PubMed  Google Scholar 

  9. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018–1028.

    Article  CAS  PubMed  Google Scholar 

  10. Klein B, Bataille R . Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am 1992; 6: 273–284.

    Article  CAS  PubMed  Google Scholar 

  11. Lauta VM . A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 2003; 97: 2440–2452.

    Article  CAS  PubMed  Google Scholar 

  12. Murakami H, Takada S, Hatsumi N, Yokohama A, Saitoh T, Uchiumi H et al. Multiple myeloma presenting high fever and high serum levels of lactic dehydrogenase, CRP, and interleukin-6. Am J Hematol 2000; 64: 76–77.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stem Cell Transplant Program in the Section of Hematology/Oncology, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA

    M Rosenzweig, D C Seldin, K Quillen, B Oran, K T Finn & V Sanchorawala

  2. Amyloid Treatment and Research Program, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA

    D C Seldin, M Skinner, K T Finn & V Sanchorawala

  3. Department of Pathology, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA

    D G Remick

Authors
  1. M Rosenzweig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D C Seldin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D G Remick
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Skinner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Quillen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B Oran
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K T Finn
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. V Sanchorawala
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V Sanchorawala.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosenzweig, M., Seldin, D., Remick, D. et al. Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a ‘melphalan recall’ reaction. Bone Marrow Transplant 45, 21–24 (2010). https://doi.org/10.1038/bmt.2009.94

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.94

Keywords

This article is cited by

Search

Advanced search

Quick links